Dexcom (DXCM) Net Margin (2010 - 2026)

Dexcom (DXCM) has 17 years of Net Margin data on file, last reported at 16.74% in Q1 2026.

• On a quarterly basis, Net Margin rose 656.0% year-over-year to 16.74% in Q1 2026; TTM through Mar 2026 was 19.31%, a 641.0% increase from a year earlier, with the FY2025 full-year figure at 17.94%, up 365.0% from the prior year.
• Net Margin for Q1 2026 stood at 16.74%, down from 21.22% in the prior quarter.
• Over the last five years, Net Margin for DXCM reached as high as 24.78% in Q4 2023 and fell as low as 6.55% in Q1 2023.
• Historically, Net Margin has averaged 14.63% across 5 years, with a median of 13.62% in 2024.
• Across the five-year window, Net Margin soared 1351 bps in 2023 and plunged 1115 bps in 2024, its largest moves.
• Year by year, Net Margin stood at 11.26% in 2022, then surged by 120 bps to 24.78% in 2023, then plunged by 45 bps to 13.62% in 2024, then jumped by 56 bps to 21.22% in 2025, then retreated by 21 bps to 16.74% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 16.74% in Q1 2026, 21.22% in Q4 2025, and 23.47% in Q3 2025.